VivoSeq
Oncology

Chronic Myeloid Leukemia, BCR-ABL1 Positive

4

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Chronic Myeloid Leukemia, BCR-ABL1 Positive is an early-stage landscape with 4 programs across 3 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

4programs
Protein / enzyme250%
Small molecule125%
Vaccine125%

Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant
Recruiting·CCity of Hope Medical Center·Phase 1·NCT07020533·46 enrolled
A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT00070499·406 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)